Drug Database
SU

sumatriptan (OPT1005 / ONZETRA Xsail / AVP825)

✓ Approved

Currax Pharmaceuticals LLC · HTR1D · 小分子

什么是 sumatriptan?

sumatriptan 是一种小分子,由Currax Pharmaceuticals LLC研发。该药已获批,用于治疗相关适应症,给药途径:Inhaled、Intranasal。

药物档案

商品名OPT1005, ONZETRA Xsail, AVP825
公司Currax Pharmaceuticals LLC
药物类别小分子
分子靶点HTR1D
给药途径Inhaled, Intranasal
状态Approved

作用机制

分子靶点

sumatriptan 作用于 1 个分子靶点:

HTR1D5-hydroxytryptamine receptor 1D (HTR1DA, HT1DA)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

sumatriptan 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersMigraine✓ Approved

相关研究文献

PubMedThe journal of headache and pain2026-11-04

PN6047 demonstrates preclinical efficacy in headache models as a novel delta-opioid receptor agonist.

Awad-Igbaria Yaseen Y, Zhang Yanping Y, Aframian Mattin M, Faas Guido C GC et al.

The Delta-opioid receptor (DOR) has gained attention as a promising target for the treatment of migraine and headache disorders. This is largely attributed to its unique pharmacological profile, which suggests that DOR-targeting treatment offers effective therapeutic effect with a lower risk of medication-overuse headache (MOH), reduced abuse liability, and minimal potential for physical dependence. These advantages have driven the development of a novel DOR agonist PN6047 (3-[[4-(dimethylcarbamoyl) phenyl]-[1-(thiazol-5-ylmethyl)-4-piperidylidene] methyl]benzamide), which has completed Phase I clinical trial and showed a favorable safety and tolerability profile. Although PN6047 has shown promising effects in neuropathic pain models, its efficacy in preclinical models of headache-associated pain remains to be evaluated. Here, we investigated the effects of PN6047 in models of migraine-associated pain and aura as well as post-traumatic headache (PTH) and MOH. C57BL/6J mice were used to examine the effects of PN6047 in the following migraine models: chronic intermittent nitroglycerin (NTG)-induced migraine-associated pain, PTH, KCl-induced cortical spreading depression (CSD), and optogenetic evoked CSD in freely behaving transgenic mice expressing ChR2-eYFP. In addition, we tested whether chronic PN6047 induced MOH and whether it could prevent the development of MOH induced by sumatriptan. A single injection of PN6047 blocked chronic cephalic allodynia established by chronic intermittent NTG and PTH. Moreover, chronic PN6047 treatment prevented the development of MOH induced by sumatriptan, without causing MOH itself. In addition, PN6047 significantly reduced the number of CSD events in the KCl-induced CSD model, and delayed CSD onset triggered in freely behaving mice along with subsequent CSD-evoked allodynia. PN6047, a novel DOR agonist, attenuates headache-associated mechanisms and symptoms in preclinical models of chronic migraine, migraine aura, PTH, and MOH. Importantly, prolonged PN6047 treatment did not induce MOH or analgesic tolerance. Together, these data demonstrate that despite the distinct mechanisms underlying migraine and headache disorder models, PN6047 exhibits significant efficacy without inducing MOH, and displays a favorable safety and tolerability profile. Not applicable.

PMID 42977916
阅读全文 →
PubMedNaunyn-Schmiedeberg's archives of pharmacology2026-10-29

Physiologically based pharmacokinetic modeling to predict sumatriptan pharmacokinetics across OCT1 functional groups.

Ji Zifan Z, Dai Tingting T, Xu Yixinyue Y, Wang Zilong Z et al.

Sumatriptan is a 5-hydroxytryptamine 1B/1D receptor agonist for acute migraine. Reduced organic cation transporter 1 (OCT1) function is associated with increased sumatriptan exposure, but its quantitative contribution to pharmacokinetic variability remains unclear. The aim of the study is to develop a whole-body physiologically based pharmacokinetic (PBPK) model describing sumatriptan PK across OCT1 functional groups and explore an exposure-matched candidate dose. A 50-mg mixed-genotype base model was developed from three clinical studies and extrapolated to 25 and 100 mg without reestimating drug-specific parameters. OCT1 functional differences were represented by changes in the effective OCT1-mediated hepatic uptake capacity (Vmax). Individuals with 0 active OCT1 alleles were compared with those with 1 or 2 active alleles. Oral doses of 20, 25, and 30 mg were explored in the 0-active-allele group using a predefined exposure-matching range of 0.80-1.25 for Cmax and AUC0-9 h. Across 50-mg studies, geometric mean fold errors were 1.25 for Cmax, 1.07 for AUC0-12 h, and 1.12 for Tmax. Across 25- and 100-mg studies, predicted-to-observed ratios ranged from 0.65 to 1.50. After 50 mg, predicted Cmax and AUC0-9 h ratios for the 0-active-allele group relative to the 1-or-2-active-allele group were 1.81 and 1.82, compared with observed ratios of 1.77 and 2.20. Both 25 and 30 mg in the 0-active-allele group met the predefined exposure-matching criterion relative to 50 mg in the 1-or-2-active-allele group, whereas 20 mg did not.The PBPK model quantified OCT1-related variability in sumatriptan disposition and supported 25 mg as a clinically feasible exploratory candidate for prospective evaluation in the 0-active-allele group.

PMID 42955297
阅读全文 →
PubMedThe European journal of neuroscience2026-10-23

Spinorphin Ameliorates Nitroglycerin-Induced Migraine-Like Responses and Trigeminovascular Neuroinflammation Potentially Through Opioid Receptor-Mediated Mechanisms.

Demir Cemalettin C, Torun Ibrahim Ethem IE, Baranoglu Kilinc Yasemin Y, Kilinc Erkan E

Enhancement of endogenous opioid signaling through inhibition of enkephalin degradation has emerged as a potential strategy for pain control, yet its role in migraine remains unclear. This study investigated whether spinorphin, an endogenous inhibitor of multiple enkephalinases, attenuates trigeminovascular activation and migraine-like responses in experimental migraine. Migraine-like pain was induced in male Wistar rats by nitroglycerin. The effects of spinorphin were evaluated using periorbital and plantar von Frey tests, followed by assessment of c-Fos levels in the trigeminal nucleus caudalis (TNC), calcitonin gene-related peptide (CGRP) levels in the trigeminal ganglion (TG) and TNC, and meningeal mast cell degranulation. Opioid receptor involvement was examined using nalmefene. In complementary ex vivo hemiskull preparations, capsaicin-evoked CGRP release was quantified, and the interaction between spinorphin and sumatriptan was investigated. Spinorphin dose-dependently alleviated cephalic and extracephalic mechanical hypersensitivity, reduced c-Fos levels, decreased CGRP concentrations in the TG and TNC, and inhibited meningeal mast cell degranulation. These protective effects were markedly attenuated by nalmefene, supporting the involvement of opioid receptor-mediated mechanisms. In ex vivo preparations, spinorphin selectively reduced capsaicin-induced CGRP levels in the superfusates without affecting basal CGRP levels, and this effect was abolished by nalmefene. Moreover, spinorphin enhanced the inhibitory effect of sumatriptan on capsaicin-stimulated CGRP levels. Spinorphin attenuates behavioral, neurochemical, and neuroinflammatory features of experimental migraine, at least partly through mechanisms involving endogenous opioid signaling. These findings suggest enkephalinase inhibition as a promising therapeutic approach for migraine and support further investigation of spinorphin as a potential adjunct to established antimigraine therapies.

PMID 42919102
阅读全文 →
PubMedJournal of cardiovascular and thoracic research2026-10-20

The Effect of Pharmacological and Non-Pharmacological Interventions on Headaches Induced by Intravenous Nitroglycerin Infusion: A Systematic Review.

Ahmadi Fatemeh F, Bagheri Nesami Masoumeh M, Abedinpour Mobina M

Nitroglycerin is a rapid-acting vasodilator commonly used as a first-line agent for the treatment of angina. Some patients receiving intravenous nitroglycerin infusion experience headaches as a side effect. Pain management is a critical priority for these patients. Therefore, this study aimed to determine the effect of pharmacological and non-pharmacological interventions on headaches induced by nitroglycerin infusion. This systematic review was conducted by searching the databases of SID, Magiran, Irandoc, Civilica, Science Direct, Web of Science, PubMed, Scopus, ProQuest, World Health Organization (WHO) and US Food and Drug Administration (FDA) and Google Scholar using the keywords "Nitroglycerin", "Glyceryl trinitrate", "Headache", "Cephalgia", "Cephalodynia", "Interventions" and "Infusion". After removing duplicates, studies were first screened based on inclusion and exclusion criteria, and their quality was then assessed. Finally, a total of 13 studies were entered into the systematic review. The total number of participants in all studies included in the review was 566 individuals aged 18 years and older. Eight studies (61.5%) addressed pharmacological interventions, and five studies (38.5%) addressed non-pharmacological interventions. The review of studies indicated that the use of cold compresses on the forehead, lavender essential oil aromatherapy, foot reflexology, sodium valproate, sumatriptan, and prednisone have proven to be effective treatments for headaches induced by nitroglycerin infusion; their use is recommended in the order mentioned for alleviating nitroglycerin-induced headaches. The use of cold compresses on the forehead, lavender essential oil aromatherapy, foot reflexology, sodium valproate, sumatriptan, and prednisone positively impacted the reduction of headaches induced by nitroglycerin infusion.

PMID 42898392
阅读全文 →
PubMedPain research & management2026-10-17

Transcranial Photobiomodulation Attenuates Neurogenic Inflammation and Sensory Hypersensitivity in a Nitroglycerin-Induced Migraine Model: Toward a Nonpharmacological Therapy.

Kazmi Sareh S, Vatandoust Seyed Mahdi SM, Athari Seyed Zanyar SZ, Ebrahimian Asal A et al.

Migraine is a debilitating neurological condition, characterized by headache, photophobia, and heightened mechanical/thermal sensitivity. Current pharmacological therapies often lead to incomplete relief and adverse effects, necessitating the use of noninvasive alternatives. This study evaluated transcranial photobiomodulation (PBM) in a nitroglycerin (NTG)-induced migraine model in male mice. Mice were assigned to Sham, NTG, NTG + Sumatriptan (SUMA; 600 µg/kg, s.c.), NTG + PBM, and NTG + PBM + SUMA groups. Over 9 days, NTG (5 mg/kg) was injected intraperitoneally every other day to develop an animal model of chronic migraine. The PBM protocol involved daily irradiation (810 nm) on the occipital bone of the head for 5 s over 9 days. The animals underwent behavioral testing for photophobia, mechanical allodynia, and thermal sensitivity. The trigeminal nucleus caudalis (TNC) was assessed for miR-155 expression by real-time PCR and protein expression of phospho-NF-κB, IL-1β, transient receptor potential ankyrin 1 (TRPA1) and vanilloid 1 (TRPV1), calcitonin gene-related peptide (CGRP), c-Fos, and pituitary adenylate cyclase-activating polypeptide (PACAP) using immunoblotting. Behavioral assessment revealed that PBM significantly reduced head scratching and improved exploratory activity, decreased light aversion, reversed periorbital/hindpaw mechanical allodynia, and prolonged thermal withdrawal latency compared to the NTG group. Moreover, PBM downregulated miR-155 expression and decreased levels of inflammatory mediators and migraine-associated neuropeptides in the TNC. Notably, combined PBM and SUMA treatment resulted in improvements in behavioral and molecular outcomes compared to either treatment alone. These results indicate that PBM inhibited migraine-like behaviors and decreased the expression of numerous molecular markers that are linked to neuroinflammation and trigeminal activation in the TNC. These findings establish a foundation for additional research on transcranial PBM as a noninvasive method for modulating migraine-related behavioral responses.

PMID 42888961
阅读全文 →
PubMedResearch square2026-09-24

Ibogalogs reduce acute and chronic headache-like behaviours in rodents by different co-modulatory mechanisms involving 5-HT1 and 5-HT2 receptor subtypes.

Chen Shuo-Fu SF, Arias Hugo R HR, Abraham Alejandro A, Wacker Daniel D et al.

The main objective of this work is to assess whether ibogalogs decrease headache-like behaviors in rats using the cortical spreading depression (CSD) and medication overuse headache (MOH) models. The CSD and MOH results showed that tabernanthalog (TBG), ibogainalog (IBG), and ibogaminalog (DM506) significantly decreased allodynia induced by acute injection of KCl or repetitive administration of sumatriptan. The effect of ibogalogs in the CSD model was sex-independent. The observed effects lasted 6-8 h, with TBG showing comparatively higher efficacy in both models. We also assessed the potential role of serotonin type 2 receptor (5-HT2R) and 5-HT1B/1DR subtypes the effects of ibogalogs using selective antagonists such as ketanserin and GR127935, respectively. The antagonist effects were headache type-dependent: in acute headache, GR127935 inhibited ibogalogs' activity during the first hour but subsequently enhanced their effects, whereas ketanserin enhanced their activities; in chronic headache, GR127935 abolished ibogalog's effects during the first 3 h, whereas ketanserin inhibited IBG's effect during the first 2 h but enhanced TBG's effect. These results suggested that the antiheadache effects of ibogalogs are mediated by co-modulation of 5-HT1R and 5-HT2R subtypes. The functional results showed the ibogalogs activate 5-HT1R subtypes with the following selectivity: 5-HT1FR ~ 5-HT1DR > 5-HT1BR >> 5-HT1ER. Thus, we compared the activity of ibogalogs between wild type (WT) and 5-HT1FR knockout (KO) mice in the MOH model. The results in WT mice showed that ibogalogs increase the facial withdrawal threshold with the following efficacy: TBG > IBG > DM506. Moreover, ibogalog antiallodynic effects were reduced in KO mice after 4 h, supporting a role for the 5-HT1FR in the actions of ibogalogs in headache attenuation. In conclusion, ibogalogs significantly reduce acute and chronic headache-like behaviors by a co-modulatory mechanism between 5-HT1R and 5-HT2R subtypes.

PMID 42779972
阅读全文 →

注册免费账户还可查看另外 3015 篇文献

免费注册查看全部文献 →

了解更多sumatriptan